Coronavirus Treatment Drugs Market, by Drug Class (Corticosteroids, Anti-viral, Monoclonal Antibodies, Kinase Inhibitors, and Others), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Dec 2020

Code : CMI4312

Pages :175

Formats :

Excel and PDF

Industry : Pharmaceutical

Coronavirus Treatment Drugs MarketSize and Trends

Coronavirus Treatment Drugs Market Report Coverage

The global coronavirus treatment drugs market is estimated to be valued at US$ 15,912 million in 2020 and is expected to exhibit a CAGR of 17.5 % during the forecast period (2020-2027).

Figure 1. Global Coronavirus Treatment Drugs Market Value (US$ Mn), 2016-2027

The increasing prevalence of COVID-19 is expected to propel growth of the global coronavirus treatment drug market during the forecast period. According to the World Health Organization’s report, manifestation of COVID-19 has resulted in more than 60.9 million infected individuals worldwide as of 27th November 2020.

Furthermore, key companies are focused on research and development of treatments which is expected to propel growth of the global coronavirus treatment drugs market during the forecast period. For instance, in May 2020, the Washington University School of Medicine started the investigational clinical trial study on efficacy of the Duvelisib drug for the treatment of COVID-19. According to researchers from theWashington University School of Medicine, Duvelisib acts by PI3K inhibition, which could potentially reduce aberrant hyperactivtation of the innate immune system, preferentially polarize macrophages, reduce pulmonary inflammation, and limit viral persistence, and improve patients' health.

Global Coronavirus Treatment Drugs Market – Impact of Coronavirus (COVID-19)

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. Currently, medication for treating COVID-19 is unavailable and several health organizations are recommending drugs which are prescribed for other health conditions but can be effective and safe for treating COVID-19.

For instance, in October 2020, the US National Library of Medicine stated that dexamethasone and remdesivir drugs can be used for the treatment of the patients suffering from severe and moderate symptoms of COVID-19. The individuals suffering from coronavirus infections are classified according to their severity of symptoms and health condition such as patients who are hospitalized but do not require oxygen; patients who are hospitalized and require oxygen, patients who are hospitalized and require non-invasive ventilation; and patients who are hospitalized and require invasive mechanical ventilation.

Figure 2. Global Coronavirus Treatment Drugs Market Share (%), By Region, 2020

North America is expected to hold dominant position in the global coronavirus treatment drugs market during the forecast period as key players are focusing on research and development of COVID-19 treatment. For instance, in June 2020, the Tufts Medical Center started investigational clinical trial study on drug Infliximab, a TNFα inhibitor therapy, which can be used in patients with severe COVID-19 symptoms and will prevent further clinical deterioration of patients with severe symptoms and reduce the need for advanced cardiorespiratory support. Currently the study is in the phase 2 of clinical trial.